Key result
Host antiviral defenses restrict SARS-CoV-2 evolution via directional mutation pressures.
Why the study?
Extensive SARS-CoV-2 sequence data highlighted directional mutation pressures exerted on the viral genome by host antiviral defense systems.
Highlights how host antiviral defense systems like APOBEC, ADAR, and ROS exert directional mutation pressures on the SARS-CoV-2 genome, influencing viral evolution.
Answers are grounded in this paper and cite their sources.
May constrain SARS-CoV-2 variant emergence; leaves open therapeutic exploitation of host defense pathways.
The extensive sequence data generated from SARS-CoV-2 during the 2020 pandemic has facilitated the study of viral genome evolution over a brief period of time. This has highlighted instances of directional mutation pressures exerted on the SARS-CoV-2 genome from host antiviral defense systems. In this brief review we describe three such human defense mechanisms, the apolipoprotein B mRNA editing catalytic polypeptide-like proteins (APOBEC), adenosine deaminase acting on RNA proteins (ADAR), and reactive oxygen species (ROS), and discuss their potential implications on SARS-CoV-2 evolution.
No takes yet. Share an insight, caveat, or question.
Mourier et al. (2020) conducted a review in SARS-CoV-2. Host antiviral defense systems, including APOBEC, ADAR, and reactive oxygen species, exert directional mutation pressures on the SARS-CoV-2 genome that restrict its evolutionary trajectory.
Synapse has enriched 10 related papers. Consider them for comparative context: